Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Monoclonal | 20 | 2023 | 875 | 3.710 |
Why?
|
| Enterotoxigenic Escherichia coli | 7 | 2023 | 22 | 2.510 |
Why?
|
| Lyme Disease | 6 | 2023 | 123 | 2.350 |
Why?
|
| Escherichia coli Infections | 6 | 2023 | 87 | 2.020 |
Why?
|
| Antibodies, Bacterial | 7 | 2023 | 181 | 1.960 |
Why?
|
| Lipoproteins | 6 | 2022 | 85 | 1.770 |
Why?
|
| Bacterial Outer Membrane Proteins | 7 | 2023 | 127 | 1.770 |
Why?
|
| Bacterial Vaccines | 6 | 2022 | 79 | 1.750 |
Why?
|
| Borrelia burgdorferi | 5 | 2023 | 93 | 1.570 |
Why?
|
| Epitopes | 7 | 2022 | 291 | 1.560 |
Why?
|
| Immunoglobulin A | 4 | 2022 | 102 | 1.510 |
Why?
|
| Antibodies, Neutralizing | 6 | 2021 | 217 | 1.440 |
Why?
|
| Single-Domain Antibodies | 2 | 2022 | 21 | 1.400 |
Why?
|
| Antigens, Surface | 6 | 2022 | 199 | 1.390 |
Why?
|
| Escherichia coli Vaccines | 3 | 2021 | 11 | 1.390 |
Why?
|
| Immunoglobulin A, Secretory | 6 | 2023 | 22 | 1.310 |
Why?
|
| Diarrhea | 3 | 2021 | 73 | 1.290 |
Why?
|
| Rabies virus | 2 | 2022 | 9 | 1.080 |
Why?
|
| Antibodies, Viral | 7 | 2023 | 325 | 1.060 |
Why?
|
| Spike Glycoprotein, Coronavirus | 4 | 2023 | 114 | 0.990 |
Why?
|
| Amino Acid Substitution | 4 | 2021 | 237 | 0.890 |
Why?
|
| Rabies Vaccines | 1 | 2022 | 4 | 0.740 |
Why?
|
| Rabies | 1 | 2022 | 8 | 0.740 |
Why?
|
| Animals | 30 | 2023 | 21259 | 0.710 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 48 | 0.700 |
Why?
|
| Ticks | 4 | 2023 | 35 | 0.690 |
Why?
|
| Immunoglobulin G | 7 | 2023 | 464 | 0.650 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 45 | 0.640 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 249 | 0.630 |
Why?
|
| Mice | 22 | 2023 | 11070 | 0.620 |
Why?
|
| Viral Envelope Proteins | 4 | 2017 | 101 | 0.580 |
Why?
|
| Hepacivirus | 2 | 2017 | 134 | 0.570 |
Why?
|
| Betacoronavirus | 1 | 2020 | 181 | 0.560 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2017 | 3 | 0.540 |
Why?
|
| Enteroendocrine Cells | 2 | 2007 | 6 | 0.530 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 260 | 0.530 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2016 | 58 | 0.490 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2016 | 15 | 0.480 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 20 | 0.480 |
Why?
|
| Immunologic Factors | 1 | 2016 | 107 | 0.450 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 2278 | 0.440 |
Why?
|
| Corynebacterium diphtheriae | 1 | 2013 | 1 | 0.410 |
Why?
|
| Diphtheria | 1 | 2013 | 5 | 0.410 |
Why?
|
| Diphtheria Antitoxin | 1 | 2013 | 4 | 0.400 |
Why?
|
| Protein Engineering | 1 | 2014 | 85 | 0.390 |
Why?
|
| Protein Binding | 5 | 2020 | 1638 | 0.370 |
Why?
|
| Immunotherapy | 2 | 2021 | 270 | 0.370 |
Why?
|
| HEK293 Cells | 4 | 2020 | 615 | 0.360 |
Why?
|
| Humans | 30 | 2023 | 64818 | 0.360 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 1286 | 0.340 |
Why?
|
| Antigens, Viral | 1 | 2011 | 130 | 0.330 |
Why?
|
| Serotonin | 2 | 2007 | 62 | 0.320 |
Why?
|
| Immunization, Passive | 3 | 2023 | 96 | 0.310 |
Why?
|
| Glycoproteins | 1 | 2011 | 189 | 0.310 |
Why?
|
| Models, Molecular | 3 | 2020 | 1159 | 0.290 |
Why?
|
| Mice, Inbred C3H | 3 | 2019 | 173 | 0.290 |
Why?
|
| Lyme Disease Vaccines | 3 | 2023 | 10 | 0.290 |
Why?
|
| Drug Design | 2 | 2021 | 137 | 0.280 |
Why?
|
| Gastrointestinal Hormones | 1 | 2007 | 10 | 0.270 |
Why?
|
| Epitope Mapping | 2 | 2021 | 52 | 0.270 |
Why?
|
| Wnt Proteins | 2 | 2007 | 104 | 0.270 |
Why?
|
| Gastrointestinal Tract | 2 | 2020 | 189 | 0.260 |
Why?
|
| Multipotent Stem Cells | 1 | 2007 | 15 | 0.260 |
Why?
|
| Retinoblastoma Protein | 1 | 2007 | 45 | 0.260 |
Why?
|
| Escherichia coli Proteins | 2 | 2021 | 275 | 0.260 |
Why?
|
| Antibody Specificity | 2 | 2020 | 102 | 0.260 |
Why?
|
| Adenoma | 1 | 2007 | 68 | 0.260 |
Why?
|
| beta Catenin | 1 | 2007 | 99 | 0.250 |
Why?
|
| Epitopes, B-Lymphocyte | 2 | 2023 | 18 | 0.240 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1380 | 0.230 |
Why?
|
| Cell Cycle | 1 | 2007 | 396 | 0.230 |
Why?
|
| Administration, Oral | 3 | 2023 | 371 | 0.220 |
Why?
|
| Hepatitis C Antibodies | 2 | 2016 | 9 | 0.220 |
Why?
|
| Liver Transplantation | 3 | 2016 | 219 | 0.220 |
Why?
|
| Caco-2 Cells | 2 | 2021 | 67 | 0.210 |
Why?
|
| Neutralization Tests | 3 | 2013 | 125 | 0.210 |
Why?
|
| Diphtheria Toxin | 2 | 2014 | 6 | 0.200 |
Why?
|
| Transfection | 2 | 2019 | 700 | 0.200 |
Why?
|
| Hepatitis C | 2 | 2016 | 145 | 0.190 |
Why?
|
| Nerve Tissue Proteins | 3 | 2013 | 428 | 0.190 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 30 | 0.190 |
Why?
|
| Hepatitis C, Chronic | 2 | 2014 | 89 | 0.190 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2022 | 6 | 0.190 |
Why?
|
| Mutation | 4 | 2020 | 2655 | 0.180 |
Why?
|
| Macaca fascicularis | 1 | 2021 | 48 | 0.170 |
Why?
|
| Cross Protection | 1 | 2021 | 6 | 0.170 |
Why?
|
| Camelids, New World | 1 | 2021 | 10 | 0.170 |
Why?
|
| Fimbriae Proteins | 1 | 2021 | 13 | 0.170 |
Why?
|
| Dogs | 1 | 2022 | 316 | 0.170 |
Why?
|
| Vero Cells | 1 | 2020 | 81 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2021 | 95 | 0.160 |
Why?
|
| Cross Reactions | 1 | 2020 | 139 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2021 | 190 | 0.160 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 86 | 0.160 |
Why?
|
| Macaca mulatta | 1 | 2021 | 260 | 0.160 |
Why?
|
| Aotidae | 1 | 2020 | 11 | 0.160 |
Why?
|
| Receptors, IgE | 1 | 2019 | 6 | 0.160 |
Why?
|
| Immunoglobulin E | 1 | 2019 | 81 | 0.150 |
Why?
|
| Hypersensitivity | 1 | 2019 | 73 | 0.150 |
Why?
|
| Antiviral Agents | 2 | 2023 | 321 | 0.140 |
Why?
|
| Cells, Cultured | 4 | 2018 | 2183 | 0.140 |
Why?
|
| Plasmids | 1 | 2019 | 293 | 0.140 |
Why?
|
| Mice, SCID | 1 | 2019 | 518 | 0.140 |
Why?
|
| Exosomes | 1 | 2018 | 53 | 0.130 |
Why?
|
| Structural Homology, Protein | 1 | 2016 | 22 | 0.130 |
Why?
|
| Amino Acid Motifs | 1 | 2016 | 156 | 0.120 |
Why?
|
| Tick Bites | 1 | 2016 | 10 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2016 | 164 | 0.120 |
Why?
|
| Crystallography, X-Ray | 1 | 2016 | 419 | 0.110 |
Why?
|
| Pregnancy Proteins | 1 | 2015 | 16 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 25 | 0.110 |
Why?
|
| Receptors, Fc | 1 | 2015 | 25 | 0.110 |
Why?
|
| Pre-Eclampsia | 1 | 2015 | 70 | 0.110 |
Why?
|
| Binding Sites | 1 | 2016 | 920 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 676 | 0.100 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2014 | 47 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 141 | 0.100 |
Why?
|
| Lysine | 1 | 2014 | 94 | 0.100 |
Why?
|
| Guinea Pigs | 1 | 2013 | 86 | 0.100 |
Why?
|
| Gels | 1 | 2014 | 77 | 0.100 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 72 | 0.100 |
Why?
|
| Glutamic Acid | 1 | 2014 | 103 | 0.100 |
Why?
|
| Static Electricity | 1 | 2014 | 170 | 0.100 |
Why?
|
| Biological Evolution | 1 | 2014 | 127 | 0.100 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2013 | 50 | 0.100 |
Why?
|
| Male | 4 | 2021 | 30880 | 0.090 |
Why?
|
| Temperature | 1 | 2014 | 314 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 463 | 0.090 |
Why?
|
| Cell Line | 2 | 2013 | 2019 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 137 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2013 | 575 | 0.090 |
Why?
|
| Intestines | 1 | 2013 | 178 | 0.090 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 221 | 0.090 |
Why?
|
| Binding Sites, Antibody | 1 | 2011 | 21 | 0.090 |
Why?
|
| Asparagine | 1 | 2011 | 25 | 0.090 |
Why?
|
| Sequence Analysis, Protein | 1 | 2011 | 31 | 0.090 |
Why?
|
| Mammals | 2 | 2023 | 220 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2011 | 251 | 0.080 |
Why?
|
| Point Mutation | 1 | 2011 | 168 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2023 | 449 | 0.080 |
Why?
|
| Cloning, Molecular | 1 | 2011 | 384 | 0.080 |
Why?
|
| RNA, Viral | 3 | 2016 | 265 | 0.070 |
Why?
|
| Biomarkers | 1 | 2014 | 1472 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5773 | 0.070 |
Why?
|
| Gastrin-Secreting Cells | 1 | 2008 | 1 | 0.070 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 2007 | 3 | 0.070 |
Why?
|
| Antibody Affinity | 2 | 2021 | 18 | 0.070 |
Why?
|
| Ghrelin | 1 | 2007 | 18 | 0.070 |
Why?
|
| Glycosylation | 2 | 2021 | 138 | 0.070 |
Why?
|
| Cricetulus | 2 | 2019 | 103 | 0.070 |
Why?
|
| CHO Cells | 2 | 2019 | 191 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2007 | 115 | 0.060 |
Why?
|
| Female | 5 | 2021 | 33854 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 1160 | 0.060 |
Why?
|
| Exons | 1 | 2007 | 205 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 276 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2008 | 2146 | 0.060 |
Why?
|
| Receptors, LDL | 1 | 2004 | 35 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2023 | 980 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2004 | 100 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 3467 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 33 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 51 | 0.050 |
Why?
|
| Zebrafish Proteins | 1 | 2004 | 168 | 0.050 |
Why?
|
| Propidium | 1 | 2022 | 3 | 0.050 |
Why?
|
| Agglutination | 1 | 2022 | 4 | 0.050 |
Why?
|
| Immune Sera | 1 | 2022 | 35 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2022 | 33 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2023 | 200 | 0.050 |
Why?
|
| Protein Domains | 1 | 2022 | 153 | 0.040 |
Why?
|
| Oligonucleotides | 1 | 2023 | 229 | 0.040 |
Why?
|
| Gastric Acid | 1 | 2021 | 9 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2022 | 295 | 0.040 |
Why?
|
| Plants, Genetically Modified | 1 | 2021 | 23 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 51 | 0.040 |
Why?
|
| Bacterial Adhesion | 1 | 2021 | 65 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 1589 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2008 | 1549 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2020 | 181 | 0.040 |
Why?
|
| Drug Stability | 1 | 2019 | 144 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2019 | 79 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 2018 | 9 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 28 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2013 | 156 | 0.030 |
Why?
|
| Lung | 1 | 2023 | 962 | 0.030 |
Why?
|
| Proteome | 1 | 2018 | 151 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 195 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2016 | 10 | 0.030 |
Why?
|
| Sofosbuvir | 1 | 2016 | 16 | 0.030 |
Why?
|
| Allografts | 1 | 2016 | 47 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2016 | 31 | 0.030 |
Why?
|
| Proof of Concept Study | 1 | 2016 | 39 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2016 | 134 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1555 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2694 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 2015 | 8 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2018 | 430 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 142 | 0.030 |
Why?
|
| Half-Life | 1 | 2015 | 81 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2015 | 202 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2015 | 185 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2015 | 138 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 491 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 364 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 609 | 0.030 |
Why?
|
| Zinc Finger Protein Gli3 | 1 | 2013 | 10 | 0.020 |
Why?
|
| Zinc Finger Protein Gli2 | 1 | 2013 | 26 | 0.020 |
Why?
|
| Child | 1 | 2023 | 4601 | 0.020 |
Why?
|
| Smoothened Receptor | 1 | 2013 | 27 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 128 | 0.020 |
Why?
|
| Mesoderm | 1 | 2013 | 89 | 0.020 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2013 | 61 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2013 | 105 | 0.020 |
Why?
|
| Tetraspanin 28 | 1 | 2012 | 4 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2012 | 33 | 0.020 |
Why?
|
| Neurons | 1 | 2018 | 932 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 654 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 740 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 312 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2013 | 281 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1009 | 0.020 |
Why?
|
| Middle Aged | 2 | 2021 | 18163 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 230 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1979 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 790 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 1774 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 662 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2013 | 3137 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2482 | 0.020 |
Why?
|
| Pyloric Antrum | 1 | 2008 | 4 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2365 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2008 | 77 | 0.020 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2013 | 514 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 300 | 0.020 |
Why?
|
| Base Sequence | 1 | 2008 | 1328 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 852 | 0.010 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2004 | 4 | 0.010 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2004 | 5 | 0.010 |
Why?
|
| Adult | 1 | 2021 | 17271 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 343 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1576 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 764 | 0.010 |
Why?
|